<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>AbbVie Inc. (ABBV) - TickerHack Deep Research</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
    <style>
        body {
            font-family: 'Inter', sans-serif;
            background-color: #F5F5F4; /* stone-100 */
            color: #374151; /* gray-700 */
        }
        .chart-container {
            position: relative;
            width: 100%;
            max-width: 600px;
            margin-left: auto;
            margin-right: auto;
            height: 300px;
            max-height: 350px;
        }
        @media (min-width: 768px) { /* md */
            .chart-container {
                height: 350px;
                max-height: 400px;
            }
        }
        .section-card {
            background-color: #FFFFFF;
            border-radius: 0.75rem; /* rounded-xl */
            box-shadow: 0 10px 15px -3px rgba(0, 0, 0, 0.07), 0 4px 6px -2px rgba(0, 0, 0, 0.04); /* Softer shadow */
            padding: 1.5rem; /* p-6 */
            margin-bottom: 2rem; /* mb-8 */
        }
        .main-title {
            font-size: 2.25rem; /* text-4xl */
            font-weight: 700; /* font-bold */
            color: #1F2937; /* gray-800 */
            margin-bottom: 1rem;
            text-align: center;
        }
        .section-title {
            font-size: 1.875rem; /* text-3xl */
            font-weight: 600; /* font-semibold */
            color: #A78BFA; /* violet-400 */
            margin-bottom: 1.5rem; /* mb-6 */
            padding-bottom: 0.5rem; /* pb-2 */
            border-bottom: 2px solid #E7E5E4; /* stone-200 */
        }
        .subsection-title {
            font-size: 1.5rem; /* text-2xl */
            font-weight: 600; /* font-semibold */
            color: #7DD3FC; /* sky-400 */
            margin-top: 1.5rem; /* mt-6 */
            margin-bottom: 1rem; /* mb-4 */
        }
        .content-text {
            line-height: 1.75;
            color: #4B5563; /* gray-600 */
            font-size: 0.95rem;
        }
        .highlight {
            color: #F97316; /* orange-500 */
            font-weight: 600;
        }
        .tab-button {
            padding: 0.5rem 1rem;
            border-radius: 0.375rem; /* rounded-md */
            font-weight: 500;
            font-size: 0.875rem; /* text-sm */
            cursor: pointer;
            transition: background-color 0.3s, color 0.3s;
            background-color: #E7E5E4; /* stone-200 */
            color: #374151; /* gray-700 */
            border: 1px solid transparent;
        }
        .tab-button.active {
            background-color: #A78BFA; /* violet-400 */
            color: #FFFFFF;
            border-color: #8B5CF6; /* violet-500 */
        }
        .nav-link {
            padding: 0.5rem 1rem;
            border-radius: 0.375rem; /* rounded-md */
            font-weight: 500;
            color: #374151; /* gray-700 */
            transition: background-color 0.2s ease-in-out, color 0.2s ease-in-out;
            white-space: nowrap;
        }
        .nav-link:hover, .nav-link.active {
            background-color: #A78BFA; /* violet-400 */
            color: #FFFFFF;
        }
        .kpi-card {
            background-color: #F9FAFB; /* gray-50 */
            border: 1px solid #E7E5E4; /* stone-200 */
            border-radius: 0.5rem; /* rounded-lg */
            padding: 1rem;
            text-align: center;
        }
        .kpi-label {
            font-size: 0.875rem; /* text-sm */
            color: #6B7280; /* gray-500 */
            margin-bottom: 0.25rem;
        }
        .kpi-value {
            font-size: 1.75rem; /* text-2xl or 3xl */
            font-weight: 600;
            color: #1F2937; /* gray-800 */
        }
    </style>
</head>
<body class="min-h-screen">

    <header class="sticky top-0 z-50 bg-white/95 backdrop-blur-md shadow-md">
        <nav class="container mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex items-center justify-between h-16">
                <div class="flex-shrink-0">
                    <h1 class="text-xl font-bold" style="color: #A78BFA;">AbbVie (ABBV) Analysis</h1>
                </div>
                <div class="hidden md:block">
                    <div class="ml-10 flex items-baseline space-x-1 lg:space-x-2">
                        <a href="#overview" class="nav-link">Overview</a>
                        <a href="#segments" class="nav-link">Business Segments</a>
                        <a href="#financials" class="nav-link">Financials</a>
                        <a href="#competition" class="nav-link">Competitive Moat</a>
                        <a href="#outlook" class="nav-link">Outlook</a>
                    </div>
                </div>
                <div class="md:hidden">
                    <button id="mobile-menu-button" type="button" class="inline-flex items-center justify-center p-2 rounded-md text-gray-500 hover:text-gray-700 hover:bg-gray-100 focus:outline-none focus:ring-2 focus:ring-inset focus:ring-violet-500" aria-controls="mobile-menu" aria-expanded="false">
                        <span class="sr-only">Open main menu</span>
                        <svg class="block h-6 w-6" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16" /></svg>
                        <svg class="hidden h-6 w-6" xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke="currentColor" aria-hidden="true"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M6 18L18 6M6 6l12 12" /></svg>
                    </button>
                </div>
            </div>
            <div class="md:hidden hidden" id="mobile-menu">
                <div class="px-2 pt-2 pb-3 space-y-1 sm:px-3">
                    <a href="#overview" class="nav-link block text-base">Overview</a>
                    <a href="#segments" class="nav-link block text-base">Business Segments</a>
                    <a href="#financials" class="nav-link block text-base">Financials</a>
                    <a href="#competition" class="nav-link block text-base">Competitive Moat</a>
                    <a href="#outlook" class="nav-link block text-base">Outlook</a>
                </div>
            </div>
        </nav>
    </header>

    <main class="container mx-auto p-4 md:p-6 lg:p-8 mt-4">

        <section id="overview" class="section-card scroll-mt-20">
            <h2 class="section-title">AbbVie: Navigating the Post-Humira World</h2>
            <p class="content-text mb-6">AbbVie Inc. (NYSE: ABBV) is a global, research-based biopharmaceutical company that spun off from Abbott Laboratories in 2013. The company is at a pivotal moment, navigating the loss of exclusivity (LoE) for its mega-blockbuster drug, Humira, which has been the best-selling drug in the world for years. AbbVie's core strategy is to manage this transition by driving strong growth from its next-generation immunology drugs, Skyrizi and Rinvoq, while expanding its presence in other key therapeutic areas like oncology, neuroscience, and aesthetics. This analysis explores AbbVie's diversified business, its financial resilience, and its prospects for growth in a new era.</p>
            
            <div class="grid md:grid-cols-2 gap-6 items-start">
                <div>
                    <h3 class="subsection-title !mt-0">Core Business Strategy</h3>
                    <p class="content-text mb-4">AbbVie's strategy is focused on a successful transition and continued innovation:</p>
                    <ul class="list-disc list-inside content-text space-y-1 pl-4">
                        <li><strong class="font-semibold text-gray-700">Offsetting Humira LoE:</strong> Driving rapid adoption and market share gains for Skyrizi and Rinvoq to replace the declining Humira revenue.</li>
                        <li><strong class="font-semibold text-gray-700">Diversification of Growth:</strong> Expanding its oncology, neuroscience, and aesthetics portfolios to create a more balanced and durable long-term growth profile.</li>
                        <li><strong class="font-semibold text-gray-700">Robust R&D Pipeline:</strong> Investing in research and development to bring new, innovative therapies to market.</li>
                        <li><strong class="font-semibold text-gray-700">Strong Shareholder Returns:</strong> A commitment to a strong and growing dividend, supplemented by strategic share repurchases.</li>
                    </ul>
                </div>
                <div class="kpi-card bg-violet-50 border-violet-200">
                    <p class="kpi-label">Skyrizi & Rinvoq Combined Sales (2024)</p>
                    <p class="kpi-value text-violet-600">$12.5 Billion</p>
                    <p class="content-text text-sm mt-2">The explosive growth of these two "heirs" to Humira is the single most important driver of AbbVie's future, with the company projecting over $27 billion in sales from them by 2027.</p>
                </div>
            </div>
        </section>

        <section id="segments" class="section-card scroll-mt-20">
            <h2 class="section-title">How AbbVie Makes Money: A Diversified Portfolio</h2>
            <p class="content-text mb-6">AbbVie's revenue is generated from the sale of its portfolio of pharmaceutical products across four key therapeutic areas. While the Immunology franchise has historically been the largest contributor, the company has built strong, multi-billion dollar businesses in Oncology, Neuroscience, and Aesthetics.</p>

            <div class="mb-6 border-b border-stone-200">
                <nav class="-mb-px flex space-x-4" aria-label="Tabs">
                    <button class="segment-tab-button active" data-target="immunology">Immunology</button>
                    <button class="segment-tab-button" data-target="oncology">Oncology</button>
                    <button class="segment-tab-button" data-target="neuro">Neuroscience</button>
                     <button class="segment-tab-button" data-target="aesthetics">Aesthetics</button>
                </nav>
            </div>

            <div id="segmentDetails">
                <div id="immunologyContent" class="segment-content">
                    <h3 class="subsection-title">Immunology Franchise</h3>
                    <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                        <div>
                            <p class="content-text mb-2">This is AbbVie's largest and most important franchise. While Humira sales are declining due to biosimilar competition, the rapid growth of Skyrizi and Rinvoq across multiple inflammatory conditions (psoriasis, arthritis, Crohn's disease) is expected to more than offset this decline and drive significant long-term growth.</p>
                        </div>
                        <div class="chart-container h-72 md:h-80">
                            <canvas id="immunologySalesChart"></canvas>
                        </div>
                    </div>
                </div>
                <div id="oncologyContent" class="segment-content hidden">
                    <h3 class="subsection-title">Oncology Franchise</h3>
                     <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                         <div>
                            <p class="content-text mb-2">AbbVie has built a significant presence in blood cancers. The franchise is led by Imbruvica (in partnership with Johnson & Johnson) and Venclexta. The company is actively investing in its pipeline to develop new cancer therapies and expand into solid tumors.</p>
                        </div>
                        <div class="kpi-card bg-sky-50 border-sky-200">
                             <p class="kpi-label">Key Products</p>
                             <p class="kpi-value text-sky-600">Imbruvica & Venclexta</p>
                             <p class="content-text text-sm mt-2">These two drugs are the pillars of the oncology business, generating several billion dollars in annual sales.</p>
                         </div>
                    </div>
                </div>
                 <div id="neuroContent" class="segment-content hidden">
                    <h3 class="subsection-title">Neuroscience Franchise</h3>
                     <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                         <div>
                            <p class="content-text mb-2">This is a major growth area for AbbVie. The franchise is anchored by the blockbuster drug Botox, which has both therapeutic (e.g., for migraine) and aesthetic uses. It is complemented by Vraylar, a fast-growing treatment for major depressive disorder and bipolar disorder, and a new portfolio of migraine drugs (Ubrelvy, Qulipta).</p>
                        </div>
                         <div class="kpi-card bg-teal-50 border-teal-200">
                             <p class="kpi-label">Blockbuster Asset</p>
                             <p class="kpi-value text-teal-600">Botox Therapeutic</p>
                             <p class="content-text text-sm mt-2">The therapeutic applications of Botox represent a large and durable multi-billion dollar business for the company.</p>
                         </div>
                    </div>
                </div>
                <div id="aestheticsContent" class="segment-content hidden">
                    <h3 class="subsection-title">Aesthetics Franchise</h3>
                     <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                         <div>
                            <p class="content-text mb-2">Acquired through the landmark purchase of Allergan, the aesthetics portfolio is led by the iconic Botox Cosmetic and the Juvederm collection of dermal fillers. This business provides diversification and generates strong cash flow, though it is more sensitive to consumer discretionary spending.</p>
                        </div>
                        <div class="chart-container h-72 md:h-80">
                            <canvas id="revenueBreakdownChart"></canvas>
                        </div>
                    </div>
                </div>
            </div>
        </section>

        <section id="financials" class="section-card scroll-mt-20">
            <h2 class="section-title">Financial Deep Dive</h2>
            <p class="content-text mb-6">AbbVie's financial profile is characterized by strong profitability and massive cash flow generation. Despite the top-line pressure from the Humira LoE, the company has maintained healthy operating margins. This financial strength allows AbbVie to invest heavily in R&D while also returning a significant amount of capital to shareholders through its best-in-class dividend.</p>
            
            <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                <div>
                    <h3 class="subsection-title">Fiscal Year Trends (2020-2024)</h3>
                    <div class="mb-4">
                        <label for="yearlyMetricSelect" class="block text-sm font-medium text-gray-700 mb-1">Select Annual Metric:</label>
                        <select id="yearlyMetricSelect" class="block w-full p-2 border border-stone-300 rounded-md shadow-sm focus:ring-violet-500 focus:border-violet-500">
                            <option value="totalRevenue" selected>Total Revenue ($B)</option>
                            <option value="netEarnings">GAAP Net Earnings ($B)</option>
                            <option value="operatingCashFlow">Operating Cash Flow ($B)</option>
                        </select>
                    </div>
                    <div id="yearlyFinancialChartContainer" class="chart-container h-80 max-w-full">
                        <canvas id="yearlyFinancialChart"></canvas>
                    </div>
                </div>

                <div>
                    <h3 class="subsection-title">Quarterly Trends (Recent 8 Qtrs)</h3>
                     <div class="mb-4">
                        <label for="quarterlyMetricSelect" class="block text-sm font-medium text-gray-700 mb-1">Select Quarterly Metric:</label>
                        <select id="quarterlyMetricSelect" class="block w-full p-2 border border-stone-300 rounded-md shadow-sm focus:ring-violet-500 focus:border-violet-500">
                            <option value="totalRevenue" selected>Total Revenue ($B)</option>
                            <option value="adjEps">Adjusted Diluted EPS ($)</option>
                        </select>
                    </div>
                    <div id="quarterlyFinancialChartContainer" class="chart-container h-80 max-w-full">
                        <canvas id="quarterlyFinancialChart"></canvas>
                    </div>
                </div>
            </div>
             <p class="content-text text-sm mt-6 text-center">The financial charts show the impact of the Humira LoE on the top line, but also highlight the company's resilient cash flow and its consistent ability to deliver strong adjusted earnings per share.</p>
        </section>

        <section id="competition" class="section-card scroll-mt-20">
            <h2 class="section-title">Competitive Moat: A Fortress of Patents and Scale</h2>
            <p class="content-text mb-6">AbbVie's competitive advantage is built on a foundation of intellectual property, a world-class R&D organization, and a massive global commercial infrastructure that allows it to effectively market and distribute its products worldwide.</p>
            
            <div class="grid md:grid-cols-2 gap-8">
                <div>
                    <h3 class="subsection-title !mt-0">Key Moats</h3>
                    <ul class="list-none space-y-3">
                        <li class="flex items-start">
                            <span class="text-violet-500 mr-2 mt-1">➔</span>
                            <span class="content-text"><strong class="text-gray-700">Intellectual Property:</strong> A vast portfolio of patents protects AbbVie's key products from generic competition for a significant period, allowing the company to earn high margins and reinvest in innovation.</span>
                        </li>
                        <li class="flex items-start">
                            <span class="text-violet-500 mr-2 mt-1">➔</span>
                            <span class="content-text"><strong class="text-gray-700">Research & Development Engine:</strong> A highly productive R&D organization with a proven track record of discovering and developing blockbuster drugs.</span>
                        </li>
                        <li class="flex items-start">
                            <span class="text-violet-500 mr-2 mt-1">➔</span>
                            <span class="content-text"><strong class="text-gray-700">Global Commercial Scale:</strong> A massive sales and marketing infrastructure that gives AbbVie the ability to launch new drugs and compete effectively in markets around the world.</span>
                        </li>
                    </ul>
                </div>
                <div>
                    <h3 class="subsection-title !mt-0">Primary Competitors</h3>
                     <ul class="list-none space-y-3">
                        <li class="flex items-start">
                            <span class="text-sky-500 mr-2 mt-1">●</span>
                            <span class="content-text"><strong class="text-gray-700">Large Biopharma Companies:</strong> Johnson & Johnson, Amgen, Bristol Myers Squibb, Merck, and Roche are major competitors across various therapeutic areas.</span>
                        </li>
                        <li class="flex items-start">
                            <span class="text-sky-500 mr-2 mt-1">●</span>
                            <span class="content-text"><strong class="text-gray-700">Biosimilar Manufacturers:</strong> Companies like Amgen, Sandoz, and Boehringer Ingelheim are now competing directly with Humira by launching lower-cost biosimilar versions.</span>
                        </li>
                         <li class="flex items-start">
                            <span class="text-sky-500 mr-2 mt-1">●</span>
                            <span class="content-text"><strong class="text-gray-700">Biotech Companies:</strong> A wide range of smaller, innovative biotech firms are developing novel therapies that could compete with AbbVie's products in the future.</span>
                        </li>
                    </ul>
                </div>
            </div>
        </section>

        <section id="outlook" class="section-card scroll-mt-20">
            <h2 class="section-title">Strategic Outlook: Risks & Rewards</h2>
            <p class="content-text mb-6">AbbVie has a clear strategy to navigate its biggest challenge and emerge as a more diversified and durable growth company. For investors, it offers a compelling combination of a high and growing dividend yield with the potential for capital appreciation.</p>
            <div class="grid md:grid-cols-2 gap-8">
                <div>
                    <h3 class="subsection-title !mt-0 text-teal-600">Rewards & Opportunities 🚀</h3>
                    <ul class="list-disc list-inside content-text space-y-2 pl-4">
                        <li><strong>Ex-Humira Growth:</strong> The rapid growth of Skyrizi, Rinvoq, Vraylar, and other key products is expected to drive a return to strong top-line growth in the coming years.</li>
                        <li><strong>Best-in-Class Dividend:</strong> As a "Dividend Aristocrat," AbbVie has a long history of raising its dividend, providing a reliable and growing income stream for investors.</li>
                        <li><strong>Strong Pipeline Potential:</strong> The company's R&D pipeline contains numerous late-stage assets with the potential to become the next generation of blockbuster drugs.</li>
                        <li><strong>Attractive Valuation:</strong> The stock often trades at a lower P/E ratio compared to the broader market and its peers, reflecting the perceived risk of the Humira LoE.</li>
                    </ul>
                </div>
                <div>
                    <h3 class="subsection-title !mt-0 text-orange-600">Risks & Challenges 📉</h3>
                    <ul class="list-disc list-inside content-text space-y-2 pl-4">
                        <li><strong>Humira Erosion:</strong> The pace and depth of Humira's sales decline due to biosimilar competition remain a key uncertainty and could be worse than expected.</li>
                        <li><strong>Pipeline Risk:</strong> Drug development is inherently risky. Any failures in late-stage clinical trials for key pipeline assets could negatively impact future growth prospects.</li>
                        <li><strong>Drug Pricing Pressure:</strong> The entire pharmaceutical industry faces political and regulatory pressure to lower drug prices, which could impact AbbVie's profitability.</li>
                        <li><strong>Dependence on Key Products:</strong> Despite diversification, the company's performance is still highly dependent on the continued success of a handful of blockbuster drugs.</li>
                    </ul>
                </div>
            </div>
        </section>

        <footer class="bg-stone-800 text-stone-300 py-8 text-center mt-12">
            <p class="text-sm">&copy; <span id="currentYearFooter"></span> TickerHack Deep Research. For informational purposes only.</p>
            <p class="text-xs mt-1">Data synthesized from AbbVie Inc. public filings (SEC 10-K & 10-Q reports) and credible financial data providers as of June 2025.</p>
        </footer>

    <script>
        document.getElementById('currentYearFooter').textContent = new Date().getFullYear();

        // Mobile menu toggle
        const mobileMenuBtn = document.getElementById('mobile-menu-button');
        const mobileMenuEl = document.getElementById('mobile-menu');
        mobileMenuBtn.addEventListener('click', () => {
            mobileMenuEl.classList.toggle('hidden');
            mobileMenuBtn.querySelectorAll('svg').forEach(svg => svg.classList.toggle('hidden'));
        });
        
        // Smooth scroll and active nav link highlighting
        const navLinks = document.querySelectorAll('header nav a[href^="#"]');
        navLinks.forEach(link => {
            link.addEventListener('click', (e) => {
                if (mobileMenuEl && !mobileMenuEl.classList.contains('hidden')) {
                    mobileMenuBtn.click(); // Close mobile menu if open
                }
                navLinks.forEach(l => l.classList.remove('active'));
                e.currentTarget.classList.add('active');
            });
        });
        
        // Segment Tabs
        const segmentTabs = document.querySelectorAll('.segment-tab-button');
        const segmentContents = document.querySelectorAll('.segment-content');
        segmentTabs.forEach(tab => {
            tab.addEventListener('click', () => {
                segmentTabs.forEach(t => t.classList.remove('active'));
                tab.classList.add('active');
                const targetId = tab.dataset.target + 'Content';
                segmentContents.forEach(content => {
                    content.id === targetId ? content.classList.remove('hidden') : content.classList.add('hidden');
                });
            });
        });

        // Chart.js Global Config
        Chart.defaults.font.family = 'Inter, sans-serif';
        Chart.defaults.color = '#4B5563';

        const CHART_COLORS = {
            violet: '#A78BFA',
            sky: '#7DD3FC',
            orange: '#FDBA74',
            stone: '#E7E5E4',
            gray: '#4B5563',
            darkViolet: '#8B5CF6',
            darkSky: '#38BDF8',
            teal: '#5EEAD4',
            pink: '#F472B6'
        };

        // Immunology Sales Chart
        const immunologySalesCtx = document.getElementById('immunologySalesChart').getContext('2d');
        new Chart(immunologySalesCtx, {
            type: 'bar',
            data: {
                labels: ['2022', '2023', '2024'],
                datasets: [
                    {
                        label: 'Humira Sales ($B)',
                        data: [21.2, 14.4, 9.8],
                        backgroundColor: CHART_COLORS.sky,
                    },
                    {
                        label: 'Skyrizi + Rinvoq Sales ($B)',
                        data: [7.8, 11.7, 12.5],
                        backgroundColor: CHART_COLORS.violet,
                    }
                ]
            },
            options: {
                responsive: true, maintainAspectRatio: false,
                scales: { x: { stacked: false }, y: { stacked: false, title: { display: true, text: 'Global Net Revenues ($B)' } } },
                plugins: { legend: { position: 'bottom' }, title: { display: true, text: 'The Changing of the Guard' } }
            }
        });
        
        // Revenue Breakdown Chart
        const revenueBreakdownCtx = document.getElementById('revenueBreakdownChart').getContext('2d');
        new Chart(revenueBreakdownCtx, {
            type: 'doughnut',
            data: {
                labels: ['Immunology', 'Neuroscience', 'Oncology', 'Aesthetics & Other'],
                datasets: [{
                    data: [42, 25, 15, 18], // Approximate FY2024 percentages
                    backgroundColor: [CHART_COLORS.violet, CHART_COLORS.sky, CHART_COLORS.teal, CHART_COLORS.orange],
                    hoverOffset: 4
                }]
            },
            options: {
                responsive: true, maintainAspectRatio: false,
                plugins: { legend: { position: 'bottom' }, title: { display: true, text: 'Revenue by Therapeutic Area (FY2024)' } }
            }
        });

        // --- FINANCIAL CHARTS LOGIC ---

        // Yearly Data Store
        const yearlyDataStore = {
            labels: ['FY20', 'FY21', 'FY22', 'FY23', 'FY24'],
            totalRevenue: { data: [45.8, 56.2, 58.1, 54.3, 54.3], label: 'Total Revenue ($B)', color: CHART_COLORS.violet },
            netEarnings: { data: [4.6, 11.5, 11.8, 4.0, 5.2], label: 'GAAP Net Earnings ($B)', color: CHART_COLORS.sky },
            operatingCashFlow: { data: [17.6, 22.2, 24.9, 19.3, 18.1], label: 'Operating Cash Flow ($B)', color: CHART_COLORS.teal }
        };

        // Quarterly Data Store
        const quarterlyDataStore = {
            labels: ['Q2 23', 'Q3 23', 'Q4 23', 'Q1 24', 'Q2 24', 'Q3 24', 'Q4 24', 'Q1 25'],
            totalRevenue: { data: [13.88, 13.93, 14.30, 13.54, 13.8, 13.7, 13.9, 12.31], label: 'Total Revenue ($B)', color: CHART_COLORS.violet },
            adjEps: { data: [2.95, 2.95, 2.72, 2.46, 2.80, 2.75, 2.79, 2.31], label: 'Adjusted Diluted EPS ($)', color: CHART_COLORS.orange }
        };

        let yearlyChart = null;
        let quarterlyChart = null;
        const yearlySelect = document.getElementById('yearlyMetricSelect');
        const quarterlySelect = document.getElementById('quarterlyMetricSelect');
        const yearlyCanvas = document.getElementById('yearlyFinancialChart').getContext('2d');
        const quarterlyCanvas = document.getElementById('quarterlyFinancialChart').getContext('2d');

        function createChart(canvas, existingChart, dataStore, metricKey) {
            if (existingChart) {
                existingChart.destroy();
            }
            const metricDetails = dataStore[metricKey];
            const isLineChart = metricKey === 'operatingCashFlow' || metricKey === 'adjEps';

            return new Chart(canvas, {
                type: 'bar',
                data: {
                    labels: dataStore.labels,
                    datasets: [{
                        label: metricDetails.label,
                        data: metricDetails.data,
                        backgroundColor: isLineChart ? 'transparent' : metricDetails.color + 'BF',
                        borderColor: metricDetails.color,
                        borderWidth: 2,
                        type: isLineChart ? 'line' : 'bar',
                        fill: !isLineChart,
                        tension: 0.1
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    scales: { 
                        y: { 
                            beginAtZero: false, 
                            title: { display: true, text: metricDetails.label.split('(')[1].replace(')','') }
                        } 
                    },
                    plugins: { legend: { display: false } }
                }
            });
        }
        
        yearlySelect.addEventListener('change', (event) => {
            yearlyChart = createChart(yearlyCanvas, yearlyChart, yearlyDataStore, event.target.value);
        });

        quarterlySelect.addEventListener('change', (event) => {
            quarterlyChart = createChart(quarterlyCanvas, quarterlyChart, quarterlyDataStore, event.target.value);
        });

        // Initial chart renders
        yearlyChart = createChart(yearlyCanvas, yearlyChart, yearlyDataStore, 'totalRevenue');
        quarterlyChart = createChart(quarterlyCanvas, quarterlyChart, quarterlyDataStore, 'totalRevenue');

    </script>
</body>
</html>

